Screener / SEC EDGAR /CIK 0001821825 /10-K filed Feb 24, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Organon & Co. OGN

Compare with peers Embed
FY2025 at a glance

Sales down 2.9%, free cash flow down to $538.0M

XBRL, from each 10-K
RevenueStatements
$6.2B from $6.4B in FY2024
FY2019FY2025
Net incomeStatements
$187.0M from $864.0M in FY2024
FY2019FY2025
Free cash flowStatements
$538.0M from $764.0M in FY2024
FY2019FY2025
EPS (diluted)Statements
$0.72 from $3.33 in FY2024
FY2019FY2025
Total debtStatements
$8.7B from $8.9B in FY2024
FY2019FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (41)
EPS (ttm)
0.78
Sales (ttm)
6.1B
Net income (ttm)
213.0M
Sales growth
-2.9%
EPS growth
-78.4%
Sales Q/Q
-1.7%
Free cash flow
675.0M
Gross margin
53.1%
Oper. margin
-
Net margin
3.5%
FCF margin
11.1%
ROA
1.6%
R&D / sales
5.9%
Dividend
0.34
Debt/Eq
7.23
Curr. ratio
2.02
Cash
1.5B
Op. cash flow (ttm)
843.0M
Net debt
7.2B
Quick ratio
1.49
Payout ratio
47.2%
FCF after stock pay
461.0M
Debt / FCF (years)
16.03
Goodwill / assets
32.3%
Tax rate
56.0%
Stock pay / sales
1.2%
Shares out.
262.6M
Shares Y/Y
+0.6%
Book / share
4.54
Cash / share
5.54
Sales / share
23.22
Asset turnover
0.46
Inventory turns
2.06
Days sales out.
78
Sales 3Y CAGR
+0.2%
Sales 5Y CAGR
-1.0%
EPS 3Y CAGR
-41.5%
EPS 5Y CAGR
-39.0%
Employees
10,000
Sales / employee
610K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2019 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 6.2B -3.7% a year Net income 187.0M -37.8% a year
FY2019 revenue 7.8B · Revenues, 0001821825-22-000002 FY2019 net income 3.2B · NetIncomeLoss, 0001821825-22-000002 7.8B FY2019 FY2020 revenue 6.5B · Revenues, 0001821825-23-000003 FY2020 net income 2.2B · NetIncomeLoss, 0001821825-23-000003 6.5B FY2020 FY2021 revenue 6.3B · Revenues, 0001628280-24-006733 FY2021 net income 1.4B · NetIncomeLoss, 0001628280-24-006733 6.3B FY2021 FY2022 revenue 6.2B · Revenues, 0001104659-25-108693 FY2022 net income 917.0M · NetIncomeLoss, 0001104659-25-108693 6.2B FY2022 FY2023 revenue 6.3B · Revenues, 0001628280-26-011125 FY2023 net income 1.0B · NetIncomeLoss, 0001628280-26-011125 6.3B FY2023 FY2024 revenue 6.4B · Revenues, 0001628280-26-011125 FY2024 net income 864.0M · NetIncomeLoss, 0001628280-26-011125 6.4B FY2024 FY2025 revenue 6.2B · Revenues, 0001628280-26-011125 FY2025 net income 187.0M · NetIncomeLoss, 0001628280-26-011125 6.2B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2019 to FY2025 (6 years).

From the same starting line, FY2019 to FY2025

Revenue, net income and free cash flow, each set to 100 in FY2019. What happened, from the 10-Ks. Not a forecast.

FY2019 = 100
50 100 Revenue: $7.8B in FY2019, $6.2B in FY2025 REVENUE $6.2B · 0.8x Net income: $3.2B in FY2019, $187.0M in FY2025 NET INCOME $187.0M · 0.1x Free cash flow: $2.9B in FY2019, $538.0M in FY2025 FREE CASH FLOW $538.0M · 0.2x FY2019 = 100FY2022FY2025
Revenue 0.8x $7.8B to $6.2B
Net income 0.1x $3.2B to $187.0M
Free cash flow 0.2x $2.9B to $538.0M

Growth per share, FY2019 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share -38.0% a year FY2019 $12.69 to FY2025 $0.72, 6 years
Book value per share -31.4% a year FY2019 $27.75 to FY2025 $2.88, 6 years
Free cash flow per share -24.9% a year FY2019 $11.55 to FY2025 $2.06, 6 years
50 100 EPS: $12.69 in FY2019, $0.72 in FY2025 EPS $0.72 · 0.1x FCF / share: $11.55 in FY2019, $2.06 in FY2025 FCF / SHARE $2.06 · 0.2x FY2019 = 100FY2022FY2025

Each line is set to 100 in FY2019, so a line at 200 has doubled. What was filed, not a forecast. A line is left out when it is not above zero in every year.

Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.72$2.88$2.06
Dec 31, 2024 $3.33$1.82$2.95
Dec 31, 2023 $3.99-$0.27$2.14
Dec 31, 2022 $3.59-$3.50$2.59
Dec 31, 2021 $5.31-$5.93$7.74
Dec 31, 2020 $8.52$21.64$8.00
Dec 31, 2019 $12.69$27.75$11.55

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $4.4B
  • − All liabilities $12.1B
  • = Net current asset value -$7.8B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $752.0M
  • − Goodwill $4.2B
  • − Other intangible assets $1.1B
  • = Tangible book value -$4.5B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

OGN against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
-2.9%144th of 155 · median +10.5%
Net margin
-4.1%15.3%
3.5%89th of 154 · median 6.8%
Return on equity
-5.2%18.5%
17.9%41st of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
11.1%68th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
7.23108th of 108 · median 0.69
OGN and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
OGN Organon & Co.$6.1B -2.9%53.1%3.5%17.9%11.1%7.23
EHC Encompass Health Corp$6.3B +10.5%-10.2%24.0%7.2%0.97
STE Steris$6.2B +8.7%44.6%13.4%11.4%15.2%0.26
INCY Incyte$6.0B +21.2%92.7%6.7%7.1%--
OPCH Option Care Health, Inc.$5.8B +13.0%19.1%3.7%16.2%4.9%0.87
RMD ResMed$5.7B +9.9%61.1%27.8%26.8%28.1%0.07
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by region

From $6.3B of sales to $1.4B of profit FY2021

  • Europe and Canada $1.7B
  • United States $1.4B
  • Latin America, Middle East, Russia, and Africa $841.0M
  • Asia Pacific and Japan $1.2B
  • China $933.0M
  • Other $233.0M
Revenue to Gross profit: $3.9BRevenue to Cost of revenue: $2.4BGross profit to Net profit: $1.4BGross profit to Costs, tax, other: $2.6B Revenue: $6.3B REVENUE $6.3B −3% Y/Y Gross profit: $3.9B · 62% margin GROSS PROFIT $3.9B 62% margin Cost of revenue: $2.4B · 38% of revenue COST OF REVENUE $2.4B 38% of revenue Net profit: $1.4B · 21% margin NET PROFIT $1.4B 21% margin · −37% Y/Y Costs, tax, other: $2.6B · 41% of revenue COSTS, TAX, OTHER $2.6B 41% of revenue

From $6.2B of sales to $917.0M of profit FY2022

  • Europe and Canada $1.6B
  • United States $1.4B
  • Latin America, Middle East, Russia, and Africa $895.0M
  • Asia Pacific and Japan $1.1B
  • China $917.0M
  • Other $151.0M
Revenue to Gross profit: $3.9BRevenue to Cost of revenue: $2.3BGross profit to Net profit: $917.0MGross profit to Costs, tax, other: $3.0B Revenue: $6.2B REVENUE $6.2B −2% Y/Y Gross profit: $3.9B · 63% margin GROSS PROFIT $3.9B 63% margin Cost of revenue: $2.3B · 37% of revenue COST OF REVENUE $2.3B 37% of revenue Net profit: $917.0M · 15% margin NET PROFIT $917.0M 15% margin · −32% Y/Y Costs, tax, other: $3.0B · 48% of revenue COSTS, TAX, OTHER $3.0B 48% of revenue

From $6.3B of sales to $1.0B of profit FY2023

Revenue to Gross profit: $3.7BRevenue to Cost of revenue: $2.5BGross profit to Net profit: $1.0BGross profit to Costs, tax, other: $2.7B Revenue: $6.3B REVENUE $6.3B +1% Y/Y Gross profit: $3.7B · 60% margin GROSS PROFIT $3.7B 60% margin · −3% Y/Y Cost of revenue: $2.5B · 40% of revenue COST OF REVENUE $2.5B 40% of revenue Net profit: $1.0B · 16% margin NET PROFIT $1.0B 16% margin · +12% Y/Y Costs, tax, other: $2.7B · 44% of revenue COSTS, TAX, OTHER $2.7B 44% of revenue

From $6.4B of sales to $864.0M of profit FY2024

Revenue to Gross profit: $3.7BRevenue to Cost of revenue: $2.7BGross profit to Net profit: $864.0MGross profit to Costs, tax, other: $2.9B Revenue: $6.4B REVENUE $6.4B +2% Y/Y Gross profit: $3.7B · 58% margin GROSS PROFIT $3.7B 58% margin · −1% Y/Y Cost of revenue: $2.7B · 42% of revenue COST OF REVENUE $2.7B 42% of revenue Net profit: $864.0M · 13% margin NET PROFIT $864.0M 13% margin · −16% Y/Y Costs, tax, other: $2.9B · 45% of revenue COSTS, TAX, OTHER $2.9B 45% of revenue

From $6.2B of sales to $187.0M of profit FY2025

  • Europe and Canada $1.6B
  • United States $1.6B
  • Latin America, Middle East, Russia, and Africa $1.1B
  • Asia Pacific and Japan $1.0B
  • China $829.0M
  • Other $93.0M
Revenue to Gross profit: $3.3BRevenue to Cost of revenue: $2.9BGross profit to Net profit: $187.0MGross profit to Costs, tax, other: $3.1B Revenue: $6.2B REVENUE $6.2B −3% Y/Y Gross profit: $3.3B · 53% margin GROSS PROFIT $3.3B 53% margin · −11% Y/Y Cost of revenue: $2.9B · 47% of revenue COST OF REVENUE $2.9B 47% of revenue Net profit: $187.0M · 3% margin NET PROFIT $187.0M 3% margin · −78% Y/Y Costs, tax, other: $3.1B · 50% of revenue COSTS, TAX, OTHER $3.1B 50% of revenue

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • Costs, tax, other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 24.9% FY2020: 39.4% net income ÷ equity
Net margin 3.0% FY2020: 33.1% profit per $ of sales: 187.0M ÷ 6.2B
Asset turnover 0.48× FY2020: 0.65× sales per $ of assets: 6.2B ÷ 12.9B
Leverage 17.11× FY2020: 1.84× assets per $ of equity: 12.9B ÷ 752.0M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    3.5% vs 6.8%
  • Gross margin down over 3 years
    62.8% → 53.3%
  • Return on equity above 15%
    17.9%
  • A profit in every one of 7 years
Net margin, FY2019 to FY2025: 41.4% to 3.0%

Balance sheet

  • Debt larger than equity
    Debt / equity 7.23 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 2.02
  • Net debt over 3 years of free cash flow
    $7.2B net debt, 10.6 years
Debt / equity at each year end, FY2019 to FY2025: 0.00 to 11.52

Cash and shareholders

  • Free cash flow positive in every one of 7 years
    $538.0M last year
  • Share count up over 5 years
    +2.9%
  • Dividend per share not up over 4 years
    $0.56 → $0.34
  • Cash from operations above net income
    $700.0M vs $187.0M
Free cash flow, FY2019 to FY2025: 2.9B to 538.0M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$3.6B of principal due, schedule of Sep 30, 2026

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

OGN's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 7. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue6.2B
FY2019: 7.8BFY2020: 6.5BFY2021: 6.3BFY2022: 6.2BFY2023: 6.3BFY2024: 6.4BFY2025: 6.2B FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income187.0M
FY2019: 3.2BFY2020: 2.2BFY2021: 1.4BFY2022: 917.0MFY2023: 1.0BFY2024: 864.0MFY2025: 187.0M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow538.0M
FY2019: 2.9BFY2020: 2.0BFY2021: 2.0BFY2022: 662.0MFY2023: 548.0MFY2024: 764.0MFY2025: 538.0M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay461.0M
FY2019: 2.9BFY2020: 2.0BFY2021: 1.9BFY2022: 587.0MFY2023: 447.0MFY2024: 659.0MFY2025: 461.0M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)0.72
FY2019: 12.69FY2020: 8.52FY2021: 5.31FY2022: 3.59FY2023: 3.99FY2024: 3.33FY2025: 0.72 FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Dividend per share0.34
FY2019: -FY2020: -FY2021: 0.56FY2022: 1.12FY2023: 1.12FY2024: 1.12FY2025: 0.34 FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares260.8M
FY2019: 253.5MFY2020: 253.5MFY2021: 254.2MFY2022: 255.2MFY2023: 256.3MFY2024: 259.2MFY2025: 260.8M FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Nexplanon/Implanon NXT 921.0M14.8% -4.4%
Zetia 342.0M5.5% +7.9%
Other 338.0M5.4% +3.0%
Atozet 324.0M5.2% -31.5%
Other Non-Opiod Pain, Bone and Dermatology 301.0M4.8% +2.0%
Arcoxia 265.0M4.3% -1.9%
Follistim AQ 264.0M4.2% +11.4%
Nasonex 262.0M4.2% -5.1%
Singulair 252.0M4.1% -29.8%
Renflexis 251.0M4.0% -8.4%
Hadlima 228.0M3.7% +60.6%
Cozaar/Hyzaar 219.0M3.5% -9.9%
Emgality 174.0M2.8% +62.6%
Other Women's Health 174.0M2.8% +10.1%
Dulera 153.0M2.5% -24.6%
Diprospan 150.0M2.4% +7.9%
Fosamax 143.0M2.3% -5.3%
Vtama 128.0M2.1% +967%
Marvelon/Mercilon 127.0M2.0% -5.2%
Other Cardiovascular 126.0M2.0% -5.3%
Clarinex 123.0M2.0% -3.1%
Propecia 118.0M1.9% +6.3%
Ganirelix Acetate Injection 101.0M1.6% -7.3%
Vytorin 100.0M1.6% -7.4%
Ontruzant 99.0M1.6% -29.8%
Proscar 97.0M1.6% +2.1%
NuvaRing 91.0M1.5% -20.9%
Other 82.0M1.3% -28.7%
Brenzys 80.0M1.3% +3.9%
Jada 74.0M1.2% +21.3%
Other Respiratory 52.0M0.8% -1.9%
Other Biosimilars 33.0M0.5% +17.9%
Rosuzet 24.0M0.4% -51.0%

10-K 0001628280-26-011125, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
International 4.6B74.2% -4.5%
Europe and Canada 1.6B26.0% -8.2%
United States 1.6B25.8% +2.0%
Latin America, Middle East, Russia, and Africa 1.1B17.2% +3.7%
Asia Pacific and Japan 1.0B16.1% -4.8%
China 829.0M13.3% -2.1%
Other 93.0M1.5% -32.1%

10-K 0001628280-26-011125, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue7.8B6.5B6.3B6.2B6.3B6.4B6.2B
Cost of revenue2.3B2.1B2.4B2.3B2.5B2.7B2.9B
Gross profit---3.9B3.7B3.7B3.3B
R&D220.0M210.0M443.0M471.0M528.0M469.0M366.0M
SG&A1.4B1.4B1.7B1.7B1.9B1.8B1.7B
Interest expense00258.0M422.0M527.0M520.0M504.0M
Pretax income3.7B2.8B1.5B1.1B673.0M807.0M425.0M
Income tax390.0M496.0M178.0M205.0M-350.0M-57.0M238.0M
Net income3.2B2.2B1.4B917.0M1.0B864.0M187.0M
EPS (diluted)12.698.525.313.593.993.330.72
Diluted shares253.5M253.5M254.2M255.2M256.3M259.2M260.8M
Depreciation & amortization49.0M56.0M92.0M96.0M120.0M132.0M156.0M
Gross margin---62.8%59.8%58.0%53.3%
Net margin41.4%33.1%21.4%14.9%16.3%13.5%3.0%
Revenue growth--16.0%-3.5%-2.1%+1.4%+2.2%-2.9%
EPS growth--32.9%-37.7%-32.4%+11.1%-16.5%-78.4%

Balance sheet

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash012.0M737.0M706.0M693.0M675.0M574.0M
Receivables-1.0B1.4B1.5B1.7B1.4B1.3B
Inventory-913.0M915.0M1.0B1.3B1.3B1.4B
Current assets-3.6B3.8B3.9B4.5B4.3B4.4B
Property & equipment-984.0M973.0M1.0B1.2B1.2B1.3B
Goodwill-4.6B4.6B4.6B4.6B4.7B4.2B
Other intangible assets-503.0M651.0M649.0M533.0M1.4B1.1B
Total assets-10.1B10.7B11.0B12.1B13.1B12.9B
Accounts payable-259.0M1.4B1.1B1.3B1.2B952.0M
Current liabilities-2.7B2.6B2.5B2.9B2.7B2.4B
Total debt-09.1B8.9B8.8B8.9B8.7B
Total liabilities---11.8B12.1B12.6B12.1B
Shareholders' equity7.0B5.5B-1.5B-892.0M-70.0M472.0M752.0M
Retained earnings-0-998.0M-331.0M443.0M1.0B1.1B

Cash flow

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow3.0B2.3B2.2B858.0M799.0M939.0M700.0M
Capital spending92.0M255.0M192.0M196.0M251.0M175.0M162.0M
Free cash flow2.9B2.0B2.0B662.0M548.0M764.0M538.0M
Stock-based pay (added back)41.0M40.0M59.0M75.0M101.0M105.0M77.0M
Free cash flow after stock pay2.9B2.0B1.9B587.0M447.0M659.0M461.0M
Dividends paid00145.0M290.0M294.0M297.0M88.0M
Debt raised009.5B080.0M1.2B1.1B
Debt repaid00112.0M108.0M338.0M1.2B1.5B
Investing cash flow-88.0M-250.0M-481.0M-420.0M-260.0M-513.0M-390.0M
Financing cash flow-2.9B-2.0B-977.0M-433.0M-569.0M-368.0M-561.0M
Dividend per share--0.561.121.121.120.34

Stock-based pay and leases

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)41.0M40.0M59.0M75.0M101.0M105.0M77.0M
Stock-based pay / revenue0.5%0.6%0.9%1.2%1.6%1.6%1.2%
Right-of-use assets-31.0M230.0M215.0M173.0M157.0M155.0M
Operating lease liabilities-31.0M230.0M199.0M171.0M156.0M156.0M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OGN/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.